Dimensional Fund Advisors LP Raises Position in Inogen, Inc. (NASDAQ:INGN)

Dimensional Fund Advisors LP raised its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 25.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 607,837 shares of the medical technology company's stock after acquiring an additional 123,208 shares during the period. Dimensional Fund Advisors LP owned approximately 2.55% of Inogen worth $5,574,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. AlphaQuest LLC purchased a new position in Inogen in the 4th quarter worth approximately $43,000. Meeder Asset Management Inc. purchased a new position in shares of Inogen in the fourth quarter worth $56,000. Integrated Quantitative Investments LLC purchased a new position in shares of Inogen in the fourth quarter worth $92,000. Ieq Capital LLC purchased a new position in shares of Inogen in the fourth quarter worth $94,000. Finally, Intech Investment Management LLC purchased a new stake in Inogen during the fourth quarter valued at $94,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Price Performance

INGN traded up $0.34 on Friday, reaching $6.09. 279,171 shares of the stock were exchanged, compared to its average volume of 236,935. The firm has a market capitalization of $163.74 million, a PE ratio of -2.71 and a beta of 1.63. The company's 50-day moving average price is $6.99 and its 200 day moving average price is $8.79. Inogen, Inc. has a fifty-two week low of $5.70 and a fifty-two week high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The business had revenue of $82.28 million during the quarter, compared to analysts' expectations of $79.57 million. As a group, equities analysts forecast that Inogen, Inc. will post -1.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

INGN has been the subject of several recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Wednesday, April 9th. Stifel Nicolaus dropped their price target on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, StockNews.com lowered Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.